An interventional study of Pharmacist-Led Counseling and education for Hypertension Management in Hypertension (HTN), sponsored by Naresuan University. Completed at 1 site in Bhutan. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Naresuan University · Not applicable, Interventional, and Health services research
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study aimed to evaluate changes in medication adherence, blood pressure, and health-related quality of life following a pharmacist-led intervention among hypertensive patients with comorbidities in Bhutan.
A single-group, pre-post quasi-experimental study was conducted at Phuentsholing General Hospital, Bhutan. Participants received pharmacist-led counseling and education focusing on hypertension management, medication adherence, prevention of complications, and lifestyle modifications. Assessments were conducted at three time points: baseline, first follow-up (approximately two months), and second follow-up (approximately four months).
Medication adherence was assessed using the Adherence to Refills and Medications Scale (ARMS), while blood pressure was measured using an automated blood pressure monitoring device. Health-related quality of life was evaluated using the EQ-5D-5L questionnaire and EQ Visual Analogue Scale (EQ-VAS). Changes in these outcomes were assessed across the three assessment periods.
The study was designed to provide evidence on changes in medication adherence, clinical outcomes, and health-related quality of life associated with pharmacist-led counseling and education among hypertensive patients with comorbidities in Bhutan.
Hypertension is a major public health concern and an important risk factor for cardiovascular disease, stroke, and kidney complications. Its management becomes increasingly challenging among patients with comorbidities because of complex medication regimens, multiple treatment requirements, and the need for sustained lifestyle modifications. Medication nonadherence may further compromise blood pressure management and overall health outcomes. In Bhutan, strengthening patient-centered approaches to chronic disease management is particularly relevant to improving the quality of care for individuals with hypertension and coexisting chronic conditions.
Pharmacists can contribute to hypertension management through medication counseling, patient education, identification of medication-related concerns, and reinforcement of appropriate medication-taking behaviors. However, evidence regarding pharmacist-led interventions among hypertensive patients with comorbidities in Bhutan remains limited. This study was undertaken to examine the potential role of structured pharmacist-led counseling and education within routine healthcare services.
The intervention consisted of individualized counseling delivered by the principal investigator, focusing on understanding hypertension, the importance of consistent medication use, potential complications of uncontrolled blood pressure, and practical strategies to improve medication adherence. Participants were also educated about lifestyle modifications, including dietary practices, physical activity, and other behaviors relevant to hypertension management. An educational brochure was used to reinforce key information and support participants' understanding of their condition and treatment.
6,125 studies on the registry are indexed under Hypertension; 910 are open to participants now.
This study's enrollment of 30 is below the median of 100 across 4,582 interventional studies indexed under Hypertension.
Browse Hypertension studies →This is the only study on the registry with Naresuan University as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants in this single-group study received pharmacist-led counseling and education focused on hypertension management, medication adherence, prevention of complications, and lifestyle modifications. The intervention was delivered at baseline and follow-up visits. Medication adherence, blood pressure, and health-related quality of life were assessed at baseline, first follow-up, and second follow-up.
Behavioral: Pharmacist-Led Counseling and education for Hypertension Management
A pharmacist-led intervention consisting of individualized counseling and patient education was provided to hypertensive patients with comorbidities. The intervention focused on improving medication adherence, enhancing understanding of hypertension and its complications, emphasizing the importance of regular medication use, and promoting lifestyle modifications. Educational materials covering hypertension management, medication adherence, and healthy lifestyle practices were used to support counseling. The intervention was delivered at baseline and subsequent follow-up visits, approximately two months apart, over a four-month follow-up period. Blood pressure, medication adherence, and health-related quality of life were assessed at baseline, first follow-up, and second follow-up.
Change in Medication Adherence
Change in medication adherence assessed using the Adherence to Refills and Medications Scale (ARMS). Lower scores indicate better medication adherence.
Time frame: Baseline, 2 months, and 4 months
Change in Blood Pressure
Change in systolic and diastolic blood pressure, measured in mmHg, from baseline to first and second follow-up assessments.
Time frame: Baseline, 2 months, and 4 months
Change of EQ-5D-5L Utility Index
Change in health-related quality of life assessed using the EQ-5D-5L questionnaire, with utility scores calculated using the Indian value set. Higher values indicate better health-related quality of life.
Time frame: Baseline, 2 months, and 4 months
Change in EQ-VAS Score
Change in self-reported health status assessed using the EQ Visual Analogue Scale (0-100), with higher scores indicating better perceived health.
Time frame: Baseline, 2 months, and 4 months
Plan to share: No — Individual participant data will not be publicly shared due to participant confidentiality and restrictions under the approved research protocol and informed consent.
No publications or documents are linked to this record.
Ran from Jun 2026 to primary completion in Aug 2026, 2 months.
Of 1,406 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 2 months is below that.
Counting every sponsor, half of 1,501 studies reached it within 23 months; a quarter within 10 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.